Abstract:Osteoarthritis (OA), in which M1 macrophage polarization in the synovium exacerbates dis-ease progression, is a major cause of cartilage degeneration and functional disabilities. Therapeutic stra-tegies of OA designed to interfere with the polarization of macrophages have rarely been reported. Here, we report that SHP099, as an allosteric inhibitor of src-homology 2-containing protein tyrosine phospha-tase 2 (SHP2), attenuated osteoarthritis progression by inhibiting M1 macrophage polarization. We demonstrated that M1 macrophage polarization was accompanied by the overexpression of SHP2 in the synovial tissues of OA patients and OA model mice. Compared to wild-type (WT) mice, myeloid line-age conditional Shp2 knockout (cKO) mice showed decreased M1 macrophage polarization and attenu-ated severity of synovitis, an elevated expression of cartilage phenotype protein collagen II (COL2), and a decreased expression of cartilage degradation markers collagen X (COL10) and matrix metalloproteinase 3 (MMP3) in OA cartilage. Further mechanistic analysis showed thatSHP099 inhibited lipopolysaccha-ride (LPS)-induced Toll-like receptor (TLR) signaling mediated by nuclear factor kappa B (NF -KB) and PI3K-AKT signaling. Moreover, intra-articular injection of SHP099 also significantly attenuated OA progression, including joint synovitis and cartilage damage. These results indicated that allosteric in-hibition of SHP2 might be a promising therapeutic strategy for the treatment of OA. 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Targeting SHP2 as a therapeutic strategy for inflammatory diseases

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

Therapeutic Potential of Targeting SHP2 in Human Developmental Disorders and Cancers

Macrophage-restricted Tyrosine Phosphatase SHP2 is a Novel Anti-Atherosclerotic Regulator

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Roles of protein tyrosine phosphatase SHP2 in lung cancer

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Advances in SHP2 Tunnel Allosteric Inhibitors and Bifunctional Molecules

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Promising Natural Products Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.

Phosphatase SHP2-mediated Mitochondrial Homeostasis for the Resolution of Inflammation

Targeting macrophagic SHP2 for ameliorating osteoarthritis<i> via</i> TLR signaling

Strategies to overcome drug resistance using SHP2 inhibitors

Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10.

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling

Protein tyrosine phosphatase non-receptor type 2 as the therapeutic target of atherosclerotic diseases: past, present and future

Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds

The Cell-Specific Role of SHP2 in Regulating Bone Homeostasis and Regeneration Niches

Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Promotes Inflammation and Accelerates Osteoarthritis by Activating β-Catenin